These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 37948842)

  • 1. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
    Nuccio A; Viscardi G; Salomone F; Servetto A; Venanzi FM; Riva ST; Oresti S; Ogliari FR; Viganò M; Bulotta A; Cameron R; Esposito A; Hines J; Bianco R; Reni M; Cascone T; Garassino MC; Torri V; Veronesi G; Cinquini M; Ferrara R
    Eur J Cancer; 2023 Dec; 195():113404. PubMed ID: 37948842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
    JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.
    Zhang SL; Tian Y; Yu J; Zhang JH; Sun L; Huang LT; Ma JT; Han CB
    Lung Cancer; 2024 May; 191():107799. PubMed ID: 38669725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis.
    Zhou Y; Li A; Yu H; Wang Y; Zhang X; Qiu H; Du W; Luo L; Fu S; Zhang L; Hong S
    JAMA Netw Open; 2024 Mar; 7(3):e241285. PubMed ID: 38451524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
    Huang H; Li L; Tong L; Luo H; Luo H; Zhang Q
    PLoS One; 2024; 19(9):e0310808. PubMed ID: 39312569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
    Villacampa G; Navarro V; Matikas A; Ribeiro JM; Schettini F; Tolosa P; Martínez-Sáez O; Sánchez-Bayona R; Ferrero-Cafiero JM; Salvador F; Papakonstantinou A; Prat A; Oliveira M; Pascual T
    JAMA Oncol; 2024 Oct; 10(10):1331-1341. PubMed ID: 39207778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials.
    Marinelli D; Gallina FT; Pannunzio S; Di Civita MA; Torchia A; Giusti R; Gelibter AJ; Roberto M; Verrico M; Melis E; Tajè R; Cecere FL; Landi L; Nisticò P; Porciello N; Occhipinti M; Brambilla M; Forde PM; Liu SV; Botticelli A; Novello S; Ciliberto G; Cortesi E; Facciolo F; Cappuzzo F; Santini D
    Crit Rev Oncol Hematol; 2023 Dec; 192():104190. PubMed ID: 37871779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
    Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
    World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials.
    Chen K; Wang X; Yue R; Chen W; Zhu D; Cui S; Zhang X; Jin Z; Xiao T
    Front Immunol; 2024; 15():1432813. PubMed ID: 39416776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials.
    Meng Y; Zhang Q; Wu R; Li H; Wang Z; Yao Y; Li X; Chen Z; Gong Y; Liu H
    Ther Adv Med Oncol; 2024; 16():17588359241284929. PubMed ID: 39376583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis.
    Han Y; Xiao X; Qin T; Yao S; Liu X; Feng Y; Li Z; Li Y; Xia S
    Cancer Immunol Immunother; 2024 Oct; 73(12):262. PubMed ID: 39382658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis.
    Xin Y; Shen G; Zheng Y; Guan Y; Huo X; Li J; Ren D; Zhao F; Liu Z; Li Z; Zhao J
    BMC Cancer; 2021 Nov; 21(1):1261. PubMed ID: 34814874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
    Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
    Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.